

## United States Patent and Trademark Office

de

DATE MAILED: 09/28/2006

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FI	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/825,382	10/825,382 04/14/2004		Chih-Ping Liu	55600-8014.US01	8686
22918	7590	09/28/2006	•	EXAMINER	
PERKINS		P	SNYDER, STUART		
P.O. BOX 2168 MENLO PARK, CA 94026			ART UNIT	PAPER NUMBER	
				1648	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
065' 4-4' 0	10/825,382	LIU ET AL.					
Office Action Summary	Examiner	Art Unit					
	Stuart W. Snyder	1648					
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address					
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period v  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tirr vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	J. nely filed the mailing date of this communication. D (35 U.S.C. § 133).					
Status							
1)⊠ Responsive to communication(s) filed on 14 Ap	oril 2004						
	action is non-final.						
· <u> </u>		secution as to the merits is					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims	,						
4)⊠ Claim(s) <u>1-15</u> is/are pending in the application.							
,	4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.							
6) Claim(s) is/are allowed.							
7) Claim(s) is/are objected to.							
8) Claim(s) 15 are subject to restriction and/or ele	ection requirement.						
5/23							
Application Papers							
9) ☐ The specification is objected to by the Examine	r.						
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correct	ion is required if the drawing(s) is obj	ected to. See 37 CFR 1.121(d).					
11)☐ The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.					
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:							
1. Certified copies of the priority documents have been received.							
2. Certified copies of the priority documents have been received in Application No							
<ol><li>Copies of the certified copies of the prior</li></ol>	ity documents have been receive	ed in this National Stage					
application from the International Bureau	ı (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list	of the certified copies not receive	d.					
Attachment(s)							
1) Notice of References Cited (PTO-892)	4) Interview Summary						
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da						
Information Disclosure Statement(s) (PTO/SB/08)     Paper No(s)/Mail Date	5)  Notice of Informal P 6)  Other:	асель Аррясацоп					
	<del></del>						

Application/Control Number: 10/825,382

Art Unit: 1648

## Election/Restrictions

This application contains claims directed to the following patentably distinct species: Various autoimmune diseases (see claim 7) and various infectious viruses (see claim 13). The species are independent or distinct because the various autoimmune diseases have different etiologies and natural disease courses. The various autoimmune diseases are thought to arise from aberrant immune responses to specific cellular antigens; experimental models are developed by inoculating specific antigens in combination with Freund's Adjuvant, for example, rheumatoid arthritis models have been developed by injecting collagen into experimental animals (see McDevitt). Likewise, it is well known in the field that the various viral diseases by definition have different etiologies and respond to various immunostimulants differently (see Medical Virology, 4<sup>th</sup> ed. especially p. 271 ff.). Human hepatitis type C and certain papilloma viral infections respond to interferon α therapy whereas human immunodeficiency virus type 1 infections do not.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species of a viral infection or an autoimmune disease for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1-5. 7-10 and 13-15 are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added; applicant must select one

Application/Control Number: 10/825,382 Page 3

Art Unit: 1648

autoimmune disease or one viral disease. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species.

MPEP § 809.02(a).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Stuart W. Snyder whose telephone number is (571) 272-9945. The examiner can normally be reached on 9:00 AM-5:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce R. Campell can be reached on (571) 272-0974. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Brun Campell

BRUCE R. CAMPELL, PH.D SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600